POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy
POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.
Frankiebx
I understand this article and the study is in reference to prep and not for treating existing HIV patients, but would this mean that descovy is forgiving in terms of resistance in adherence in HIV patients ?
October 4, 2020 • New York